Uric Acid Metabolism Was Altered In Isolated Colonic Crohn’s Disease But Not Ulcerative Colitis.

ibdwatch

Uric Acid Metabolism Was Altered In Isolated Colonic Crohn’s Disease But Not Ulcerative Colitis. J Gastroenterol Hepatol. 2018 Jun 21;: Authors: Zhu F, Feng D, Zhang T, Gu L, Zhu W, Guo Z, Li Y, Lu N, Gong J, Li N Abstract BACKGROUND: Patients with inflammatory bowel disease (IBD) have higher incidence of developing nephrolithiasis. Increased uric acid production induced by Saccharomyces cerevisiae exacerbates colitis in mice. We aimed to evaluate the association between serum uric acid level and disease activity in IBD population. METHODS: Four hundred and thirty-five patients…

Read More

No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

ibdwatch

Related Articles No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 Jun 21;: Authors: Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ Abstract OBJECTIVES: 5-aminosalicylates (5-ASA) are frequently continued in patients with moderate-severe ulcerative colitis (UC), even after escalation to biologic agents, without evaluation of the benefit of this approach. We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and…

Read More

Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD.

ibdwatch

Related Articles Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. Am J Gastroenterol. 2018 Jun 21;: Authors: Targownik LE, Leung S, Lix LM, Singh H, Bernstein CN Abstract OBJECTIVES: Immunomodulator (IM)-based monotherapy with thiopurines or methotrexate is being increasingly supplanted in the management of moderate-to-severe IBD by more efficacious biologic agents. However, given their low cost, IMs may still have a selective role in this setting. METHODS: We used a Canadian population-based dataset of persons with IBD spanning from 1996 until…

Read More

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.

ibdwatch

Related Articles NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018 Jun 19;: Authors: Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, Nishida A, Nakagawa S, Miura M, Toyonaga T, Onodera K, Shinozaki M, Ishiguro Y, Mizuno S, Takahara M, Yanai S, Hokari R, Nakagawa T, Araki H, Motoya S, Naito T, Moroi R, Shiga H, Endo K, Kobayashi T, Naganuma M, Hiraoka S, Matsumoto T, Nakamura S,…

Read More

Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease.

ibdwatch

Related Articles Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Singh S, Fumery M, Sandborn WJ, Murad MH Abstract BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn’s disease (CD). AIM: We assessed comparative efficacy and safety of first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor [TNF]-α) agents) biologic therapy for moderate-severe CD, through a systematic review and network meta-analysis, and appraised quality of evidence (QoE) using the Grading of…

Read More

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.

ibdwatch

Related Articles Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflamm Bowel Dis. 2018 Jun 15;: Authors: Bossuyt P, Baert F, D’Heygere F, Nakad A, Reenaers C, Fontaine F, Franchimont D, Dewit O, Van Hootegem P, Vanden Branden S, Lambrecht G, Ferrante M, Belgian IBD Research and Development Group Abstract Background: Golimumab (GOL) is registered for moderate to severely active ulcerative colitis (UC). Data on the use of GOL in daily clinical practice are limited.…

Read More

A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study.

ibdwatch

Related Articles A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study. Inflamm Bowel Dis. 2018 Jun 15;: Authors: Lee CK, Melmed GY, Mann A, Danovitch I, Hedrick R, McGovern DPB, Targan S, Shih D, Vasiliauskas E, IsHak WW, Feldman E Abstract Background: This study reports on the logistics and feasibility of a novel multidisciplinary approach to biopsychosocial care at a tertiary adult inflammatory bowel disease (IBD) center. Methods: Consecutive patients referred for a new IBD consultation completed the following self-assessments: the Short Form-12, the…

Read More

Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: A pilot study.

ibdwatch

Related Articles Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: A pilot study. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Rowan CR, Keegan D, Byrne K, Cullen G, Mulcahy HE, Sheridan J, Ryan EJ, de Vries A, D’Haens G, Doherty GA Abstract BACKGROUND: Ustekinumab (USK) is licenced for intravenous induction and subcutaneous (S/C) maintenance in Crohn’s disease. AIM: To evaluate ustekinumab trough concentrations and clinical response with exclusive subcutaneous ustekinumab induction. METHODS: Patients with Crohn’s disease who initiated treatment with subcutaneous…

Read More

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease.

ibdwatch

Related Articles An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V Abstract BACKGROUND: Fibrotic stricture is a common complication of Crohn’s disease (CD) affecting approximately half of all patients. No specific…

Read More
<< Go Back